AxoGen is a biotech company developing treatment options for the reconstruction and repair of peripheral nerve injuries. It is passionate about restoring nerve function and quality of life to patients with peripheral nerve injuries by providing innovative, clinically proven and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body.
AxoGen's portfolio of products includes Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard Nerve Connector, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed nerves, AxoGuard Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments and Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that may be used as a soft tissue covering to reduce inflammation and scar tissue formation. 

Show more
Type
Public
HQ
Alachua, US
Founded
2002
Size (employees)
114 (est)+41%
AxoGen was founded in 2002 and is headquartered in Alachua, US
Report incorrect company information

Key People/Management at AxoGen

Karen Zaderej

Karen Zaderej

CEO
Gregory G. Freitag

Gregory G. Freitag

General Counsel, SVP Business Development, Director

AxoGen Office Locations

AxoGen has offices in Burleson and Alachua
Alachua, US (HQ)
13631 Progress Blvd
Burleson, US
300 Boone Rd
Show all (2)
Report incorrect company information

AxoGen Financials and Metrics

AxoGen Financials

AxoGen's revenue was reported to be $60.43 m in FY, 2017
USD

Revenue (Q1, 2018)

17.3 m

Gross profit (Q1, 2018)

14.5 m

Gross profit margin (Q1, 2018), %

84.3%

Net income (Q1, 2018)

(5.6 m)

EBIT (Q1, 2018)

(5 m)

Market capitalization (15-May-2018)

1.5 b

Closing share price (15-May-2018)

43.1

Cash (31-Mar-2018)

30.6 m
AxoGen's current market capitalization is $1.5 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

10.9 m16.8 m27.3 m41.1 m60.4 m

Revenue growth, %

54%63%50%

Cost of goods sold

2.4 m3.4 m4.8 m6.5 m9.3 m

Gross profit

8.5 m13.4 m22.5 m34.6 m51.1 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Revenue

3 m3.1 m4.2 m4.7 m5 m6.4 m8.2 m8.1 m10.4 m11.2 m12.2 m15.2 m16 m17.3 m

Cost of goods sold

650.2 k701.3 k887.8 k896.2 k982.9 k1 m1.4 m1.4 m1.5 m1.7 m1.9 m2.3 m2.5 m2.7 m

Gross profit

2.3 m2.4 m3.3 m3.8 m4 m5.4 m6.7 m6.7 m8.8 m9.5 m10.3 m12.9 m13.5 m14.5 m

Gross profit Margin, %

78%78%79%81%80%84%83%83%85%85%84%85%84%84%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

20.1 m8.2 m25.9 m30 m36.5 m

Accounts Receivable

1.2 b

Inventories

3.4 m3.2 m3.9 m5.5 m7.3 m

Current Assets

25.7 m14.4 m35.1 m44 m55.7 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

22.6 m16.8 m14.2 m11.8 m19.3 m15.6 m29.9 m20.9 m18.3 m16 m25.9 m23.9 m22 m30.6 m

Accounts Receivable

1.7 m

Inventories

3.5 m3.5 m3.4 m3.3 m3.3 m3.5 m3.7 m4.5 m4.8 m5 m5.9 m6.3 m6.7 m8.1 m

Current Assets

28 m22.4 m20.3 m18 m26 m23.2 m38.6 m31.5 m29.7 m28.7 m40.9 m40.2 m39.5 m51.7 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(14.6 m)(17.7 m)(13.4 m)(14.4 m)(10.4 m)

Depreciation and Amortization

138.3 k198.9 k249 k487.6 k

Inventories

(247.3 k)184.8 k(720.3 k)5.5 m(1.9 m)

Accounts Payable

430.6 k498.3 k1.1 m7 m1.9 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(3.6 m)(4.2 m)(3.7 m)(3.2 m)(3.6 m)(3.2 m)(3 m)(3.7 m)(2.8 m)(2.3 m)(3.8 m)(5.6 m)

Depreciation and Amortization

199.5 k

Inventories

3.4 m3.3 m3.3 m3.5 m3.7 m4.5 m4.8 m5 m5.9 m(737 k)

Accounts Payable

2.2 m2 m3.4 m3.4 m4.1 m3.8 m3.9 m4.6 m6.7 m(241.4 k)
USDY, 2018

Financial Leverage

2.5 x
Show all financial metrics
Report incorrect company information